Multicenter, Double-Blinded, Randomized, Comparator-Controlled Noninferiority Trial to Compare the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Plasma (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Entegrion
- 31 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 31 Dec 2018.
- 16 Oct 2018 New trial record